EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim

Karen Cornelissen iD, John H Rex, Daniela Zinzi, Derek Law, Rachel Upcott Gill, Hannah M Jones, Johan Maertens, Sharon C-A Chen, Roger Brüggemann iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01745-25 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Karen Cornelissen und 8 weiteren Autor:innen. Beteiligte Einrichtung: F2G Ltd, Nether Alderley, Macclesfield, United Kingdom. Hauptthemen laut MEDLINE: Antifungal Agents, Cytochrome P-450 Enzyme System, Piperazines, Pyrimidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Olorofim is a novel oral antifungal agent which selectively inhibits the fungal enzyme dihydroorotate dehydrogenase found in molds including Aspergillus , Scedosporium , Lomentospora , and Scopulariopsis and in dimorphic fungi such as Coccidioides . Based on in vitro studies, clinical pharmacology, and pharmacokinetic (PK) data from the Phase 2b FORMULA study (F901318/0032) as well as physiologically based PK (PBPK) modeling of drug interactions, the drug’s CYP-mediated interactions are now well understood. Olorofim is mainly metabolized by cytochrome P450 (CYP) CYP3A4, with minor contributions from CYP2C8 and CYP2C9. In vitro studies found that it inhibits CYP3A4, weakly inhibits CYP2D6 and CYP2C8, and weakly induces CYP1A2 and CYP2B6. Phase I studies confirm it is predominantly cleared by CYP3A4 and weakly inhibits CYP3A4. In the Phase 2b FORMULA study, co-administered sensitive CYP3A4 substrates required limited dose reductions when using olorofim. When used with strong CYP3A4 inhibitors, dual moderate inhibitors like fluconazole, or CYP3A4 inducers, dose adjustments were needed for olorofim. Physiologically based PK (PBPK) modeling predicted moderate effects with CYP3A4 inhibitors or inducers and negligible effects with weak CYP3A4 inhibitors or strong inhibitors of CYP2D6, CYP2C8, and CYP2C9. Overall, the drug’s interaction profile is predictable and manageable, making it a suitable candidate drug to use in treating patients with invasive fungal disease (IFD), who often require polypharmacy. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT02680808 , NCT02730442 , NCT02737371 , NCT04171739 , NCT03340597 , and NCT03583164 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCytochrome P-450 Enzyme SystemPiperazinesPyrimidinesHumansBiphenyl CompoundsCytochrome P-450 CYP1A2Cytochrome P-450 CYP2B6Cytochrome P-450 CYP2C8Cytochrome P-450 CYP2C9Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsDrug InteractionsFluconazoleAcetamidesPyrroles

Stichwörter der Autor:innen

drug interactionolorofim

Substanzen

Antifungal AgentsBiphenyl CompoundsCYP1A2 protein, humanCYP2B6 protein, humanCYP2C8 protein, humanCYP2C9 protein, humanCYP3A4 protein, humanCytochrome P-450 CYP1A2Cytochrome P-450 CYP2B6Cytochrome P-450 CYP2C8

Autor:innen und Institutionen

  • F2G Ltd, Nether Alderley, Macclesfield, United Kingdom.
  • Cyprotex Discovery Ltd, Macclesfield, United Kingdom.
  • Certara UK Ltd, Sheffield, United Kingdom.
  • Department of Hematology, University Hospitals Leuven, Leuven, Belgium.
  • Centre for Infectious Diseases and Microbiology Laboratory Services, Department of Infectious Diseases, Institute for Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, The Uni…
  • Radboud University Medical Centre, Nijmegen, the Netherlands.

ORCID-Profile: Karen Cornelissen, Roger Brüggemann

Zitieren

APA

Cornelissen, K., Rex, J. H., Zinzi, D., Law, D., Upcott Gill, R., Jones, H. M., Maertens, J., Chen, S. C. A., & Brüggemann, R. (2026). Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01745-25

Vancouver

Cornelissen K, Rex JH, Zinzi D, Law D, Upcott Gill R, Jones HM, et al. Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01745-25

BibTeX
@article{Cornelissen2026,
  author = {Cornelissen, Karen and Rex, John H and Zinzi, Daniela and Law, Derek and Upcott Gill, Rachel and Jones, Hannah M and Maertens, Johan and Chen, Sharon C-A and Brüggemann, Roger},
  title = {Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01745-25}
}
Kostenlos starten →